^
Association details:
| Biomarker: | ALK negative + TP53 deletion |
|---|---|
| Cancer: | T Cell Non-Hodgkin Lymphoma |
| Regimen: | CHOP (cyclophosphamide + doxorubicin hydrochloride + + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis
Published date:
12/16/2021
Excerpt:
...six leukemic ALK-negative ALCL cases and all (100%) had TP53 deletion...Eight of nine (90%) patients with leukemic ALK-negative ALCL died, and their overall survival was significantly shorter than that of the patients with non-leukemic...In the leukemic group, seven of nine (78%) patients were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or modified CHOP.
DOI:
10.3390/cancers13246316
